Cardiology has been shifting from reactionary treatment strategies to a greater emphasis on prevention. This is an especially important trend in heart failure, which is associated with high costs and rising hospitalization rates. 

Reducing the activity of a specific protein could provide significant relief for many heart failure patients.

A new comprehensive report detailed the latest stats and trends in hypertension, coronary heart disease, stroke and many other areas of interest. “Progress in cardiovascular health depends on knowing where we stand,” the authors wrote. “To improve, we must measure—not occasionally, but consistently, transparently and with purpose.”

The device, currently just a prototype, could be the first of its kind to gain FDA approval.

Early evidence suggests CBD could help clinicians treat pericarditis, myocarditis and other significant heart conditions. Additional research is still required, however, including many more clinical trials.

Cardiologists often use the word “stable” when describing a heart failure patient who is recovering or showing signs of improvement. That word, however, could be giving patients a false sense of security—and it could even do harm to their long-term health. 

Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo.